

Johan M Kros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4658574/publications.pdf>

Version: 2024-02-01

101
papers

6,567
citations

87888

38
h-index

69250

77
g-index

102
all docs

102
docs citations

102
times ranked

9627
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 53-62.	2.0	13
2	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
3	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
4	A unified 3D map of microscopic architecture and MRI of the human brain. Science Advances, 2022, 8, eabj7892.	10.3	33
5	Novel Antibodyâ€“Peptide Binding Assay Indicates Presence of Immunoglobulins against EGFR Phospho-Site S1166 in High-Grade Glioma. International Journal of Molecular Sciences, 2022, 23, 5061.	4.1	2
6	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	1.6	23
7	Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia. Journal of Hematopathology, 2021, 14, 79-83.	0.4	6
8	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
9	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
10	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34
11	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
12	EPEN-10. UNRAVELLING THE TUMOR IMMUNE MICROENVIRONMENT OF POSTERIOR FOSSA A EPENDYMOMAS ON RNA AND PROTEIN EXPRESSION LEVELS. Neuro-Oncology, 2021, 23, i15-i15.	1.2	0
13	Differential Expression of BOC, SPOCK2, and GJD3 Is Associated with Brain Metastasis of ER-Negative Breast Cancers. Cancers, 2021, 13, 2982.	3.7	4
14	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 Oncology, The, 2021, 22, 813-823.	10.7	132
15	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
16	Cerebral Metastasis of Common Cancers. Cancers, 2021, 13, 65.	3.7	0
17	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	1.2	140
18	Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Journal of Clinical Oncology, 2020, 38, 81-99.	1.6	84

#	ARTICLE	IF	CITATIONS
19	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11
20	Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 863-872.	1.7	20
21	Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa040.	0.7	3
22	The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 1087.	2.8	22
23	Phosphorylation Ratio Determination in Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Tissue with Targeted Mass Spectrometry. <i>Journal of Proteome Research</i> , 2020, 19, 4179-4190.	3.7	6
24	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. <i>Frontiers in Oncology</i> , 2020, 10, 596.	2.8	13
25	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	7.7	344
26	DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. <i>Drug Discovery Today</i> , 2020, 25, 951-955.	6.4	7
27	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-NOW meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
28	CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions. <i>Angiogenesis</i> , 2019, 22, 75-93.	7.2	61
29	Circulating Proangiogenic Cells and Proteins in Patients with Glioma and Acute Myocardial Infarction: Differences in Neovascularization between Neoplasia and Tissue Regeneration. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	1.3	5
30	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz001.	0.7	9
31	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. <i>Scientific Reports</i> , 2019, 9, 14643.	3.3	44
32	BSCI-25. THE ROLE OF THE IFN γ PATHWAY IN BREAST CANCER BRAIN METASTASIS FORMATION. <i>Neuro-Oncology Advances</i> , 2019, 1, i5-i5.	0.7	0
33	Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies. <i>Trends in Immunology</i> , 2019, 40, 274-278.	6.8	7
34	TMX2 Is a Crucial Regulator of Cellular Redox State, and Its Dysfunction Causes Severe Brain Developmental Abnormalities. <i>American Journal of Human Genetics</i> , 2019, 105, 1126-1147.	6.2	25
35	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 4784.	2.5	4
36	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	27.8	129

#	ARTICLE	IF	CITATIONS
37	Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. <i>Drug Discovery Today</i> , 2018, 23, 1175-1182.	6.4	142
38	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 349-357.	2.9	24
39	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. <i>Acta Neuropathologica</i> , 2018, 135, 581-599.	7.7	63
40	Breast cancer brain metastasis: molecular mechanisms and directions for treatment. <i>Neuro-Oncology</i> , 2018, 20, 1439-1449.	1.2	66
41	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. <i>Neuro-Oncology</i> , 2018, 20, 103-112.	1.2	220
42	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	10.5	50
43	IMMU-02. PROTEOMIC ANALYSIS IDENTIFIED CECR1 MEDIATED RESPONSE IN MACROPHAGE AND TUMOR ASSOCIATED MACROPHAGE. <i>Neuro-Oncology</i> , 2018, 20, i98-i99.	1.2	0
44	NIMG-75. WHO 2016 GRADE II GLIOMA MOLECULAR SUBTYPES HAVE A DISTINCT SPATIAL DISTRIBUTION PATTERN. <i>Neuro-Oncology</i> , 2018, 20, vi192-vi192.	1.2	0
45	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. <i>Acta Neuropathologica Communications</i> , 2018, 6, 126.	5.2	38
46	Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. <i>Frontiers in Oncology</i> , 2018, 8, 159.	2.8	15
47	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
48	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 928-934.	1.5	9
49	HGG-04. PERICYTE-DERIVED PERIOSTIN IS CRUCIAL FOR NEO-VESSEL FORMATION IN GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i89-i89.	1.2	0
50	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology</i> , 2018, 19, 1170-1179.	10.7	80
51	Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors. <i>Oncotarget</i> , 2018, 9, 33500-33514.	1.8	18
52	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	1.2	381
53	CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1098-1114.	2.4	30
54	Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. <i>Acta Neuropathologica Communications</i> , 2017, 5, 4.	5.2	61

#	ARTICLE	IF	CITATIONS
55	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2009-2018.	3.6	54
56	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
57	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , 2017, 19, 614-624.	1.2	100
58	Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression. <i>Neuro-Oncology</i> , 2017, 19, now251.	1.2	44
59	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. <i>Acta Neuropathologica</i> , 2017, 134, 957-959.	7.7	87
60	Mutations targeting the coagulation pathway are enriched in brain metastases. <i>Scientific Reports</i> , 2017, 7, 6573.	3.3	10
61	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653.	13.7	307
62	The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. <i>Neuro-Oncology</i> , 2017, 19, 1435-1446.	1.2	121
63	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2017, 57, 314-325.	2.3	19
64	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2394-2401.	1.6	142
65	Improving the characterization of endothelial progenitor cell subsets by an optimized FACS protocol. <i>PLoS ONE</i> , 2017, 12, e0184895.	2.5	41
66	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 775-786.	2.8	64
67	Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. <i>Journal of Experimental Medicine</i> , 2016, 213, 1163-1174.	8.5	224
68	Myocarditis in patients with subarachnoid hemorrhage: A histopathologic study. <i>Journal of Critical Care</i> , 2016, 32, 196-200.	2.2	28
69	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
70	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016, 18, 388-400.	1.2	143
71	Circulating glioma biomarkers. <i>Neuro-Oncology</i> , 2015, 17, 343-60.	1.2	73
72	Pregnancy Zone Protein is Increased in the Alzheimer's Disease Brain and Associates with Senile Plaques. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 227-238.	2.6	17

#	ARTICLE	IF	CITATIONS
73	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS ONE, 2015, 10, e0144097.	2.5	6
74	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology, 2015, 17, 935-941.	1.2	136
75	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. European Journal of Cancer, 2015, 51, 893-903.	2.8	21
76	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology, 2015, 33, 1943-1950.	1.6	21
77	Contemporary frameless intracranial biopsy techniques: Might variation in safety and efficacy be expected?. Acta Neurochirurgica, 2015, 157, 2011-2016.	1.7	30
78	AT-34 CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	1.2	0
79	Fast Tracking of Co-localization of Multiple Markers by Using the Nanozoomer Slide Scanner and NDPViewer. Journal of Cellular Physiology, 2014, 229, 967-973.	4.1	14
80	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	7.7	54
81	Intratumoral, not circulating, endothelial progenitor cells share genetic aberrations with glial tumor cells. Journal of Cellular Physiology, 2013, 228, 1383-1390.	4.1	6
82	A Proteome Comparison Between Physiological Angiogenesis and Angiogenesis in Glioblastoma. Molecular and Cellular Proteomics, 2012, 11, M111.008466.	3.8	41
83	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	19
84	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	6
85	Grading of Gliomas: The Road From Eminence to Evidence. Journal of Neuropathology and Experimental Neurology, 2011, 70, 101-109.	1.7	51
86	Challenge of the gap between the current mania of cancer stem cells and the therapeutic strategy for patients with cancer. International Journal of Cancer, 2010, 126, 1529-1530.	5.1	1
87	Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Annals of Neurology, 2010, 68, 835-844.	5.3	84
88	Expression Sites of Colligin 2 in Glioma Blood Vessels. Brain Pathology, 2010, 20, 50-65.	4.1	13
89	Circulation status of subintestinal vessels is a sensitive parameter for monitoring suboptimal systemic circulation in experimental zebrafish embryos. Cell Cycle, 2009, 8, 3782-3783.	2.6	1
90	Cell proliferation and migration are mutually exclusive cellular phenomena in vivo: Implications for cancer therapeutic strategies. Cell Cycle, 2009, 8, 950-951.	2.6	15

#	ARTICLE	IF	CITATIONS
91	Haemoglobin staining for in vivo portraying of functional vasculature in experimental zebrafish embryos. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 823-824.	2.1	3
92	Intratumoral Distribution of 1p Loss in Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1118-1123.	1.7	9
93	Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 545-551.	1.7	143
94	Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. <i>Annals of Neurology</i> , 2007, 62, 40-48.	5.3	59
95	Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. <i>FASEB Journal</i> , 2007, 21, A26.	0.5	0
96	Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. <i>Cancer</i> , 2006, 106, 388-395.	4.1	83
97	Peptide profiling of cerebrospinal fluid by mass spectrometry. <i>Expert Review of Proteomics</i> , 2006, 3, 297-309.	3.0	12
98	Differential expression of Hela-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells. <i>Journal of Pathology</i> , 2005, 205, 408-414.	4.5	30
99	Glioblastoma Multiforme. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 260.2-260.	1.7	0
100	Identification of Tumor-Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 855-862.	1.7	98
101	Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma. <i>Journal of Neurosurgery</i> , 2002, 97, 1390-1396.	1.6	18